Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 1st Preview)
-
Immuno-oncology engineering and macrophage-mediated tumor killing
A Nature Communications study led by Pagès-Geli, Ribeiro, Wienclaw and colleagues reports a high-throughput approach to engineer bispecific antibodies designed to boost macrophage killing of malignant B cells. The work focuses on improving the immune synapse between engineered antibody formats and macrophage effector functions, aiming to increase the probability that targeted B-cell lymphoma cells are eliminated.
-
Preoperative immunotherapy in high-risk early HER2-negative breast cancer
In the adaptive I-SPY2 platform, researchers reported that a preoperative dual-immunotherapy regimen added to chemotherapy produced substantially higher tumor eradication rates in patients with high-risk, early-stage HER2-negative breast cancer. The strategy aimed to improve pathologic complete response by changing the immune milieu before surgery.
-
AI evaluation for frontier drug-discovery models
Insilico Medicine launched what it says is the first Drug Discovery and Development Benchmark as a Service for frontier AI models, designed to test whether systems can make meaningful scientific decisions rather than overfitting to training data recall. The benchmark is positioned as a response to weaknesses in existing evaluations that may not reflect real-world drug discovery workflows.
-
FDA advisory support for intratumoral RP1 plus checkpoint blockade
A panel of FDA advisers voted in favor of Replimune’s oncolytic melanoma therapy RP1 when used in combination with a PD-1 inhibitor, signaling improved odds for approval after prior submissions were rejected. In the meeting, panelists concluded the pivotal efficacy results were evaluable and clinically meaningful, despite FDA scientists’ concerns about trial design and interpretability.
-
NovaNordisk’s IL-6 pathway bet derailed in Phase 3
Novo Nordisk’s Phase 3 Zeus trial of ziltivekimab missed the primary endpoint in reducing major adverse cardiovascular events versus placebo. The company reported the mechanism reduced IL-6 pathway activity and lowered high-sensitivity C-reactive protein, but the effect did not translate into statistically meaningful risk reduction across enrolled populations.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.